Citi is bullish on WuXi AppTec: TIDES and small-molecule D&M support above-industry growth beyond 2026

Overview

This report is Citi’s quick take following its visit to WuXi AppTec’s Shanghai headquarters on June 15, 2026 and its discussion with the investor relations head. The core conclusion is that while maintaining its 2026 revenue guidance, WuXi AppTec continues to convert pipelines in its TIDES and small-molecule D&M businesses, improve margin trends, enhance production efficiency through AI, and advance overseas capacity under a multi-region strategy, giving the company the ability to sustain above-industry growth in 2026 and beyond.

Core views

Citi believes WuXi AppTec’s growth is primarily driven by two businesses: small-molecule manufacturing and TIDES. In 1Q26, small-molecule CDMO revenue grew 80% YoY, and TIDES still guides for 40% revenue growth in 2026, while solid-phase peptide synthesis capacity is expected to increase from 100,000L in 3Q25 to 130,000L in 2026. On margins, the current gross margin of the chemistry business is close to 50%, in line with the company’s previous long-term gross margin guidance of 45%-50%, though the ramp-up of overseas capacity may temporarily weigh on overall gross margin. On regulation, management believes the impact of 1260H and the Biosecure Act is limited, with revenue exposure to federally funded projects below 1% and a five-year grace period under the Biosecure Act.

Analysis framework

The report combines headquarters field research, management discussions, 2026 revenue guidance, business-line growth momentum, margin trends, overseas capacity expansion, geopolitical regulatory risks, and an NPV-based SOTP valuation framework for its assessment.

Methodology notes

• Valuation frameworkNPV-based SOTP

  Sum-of-the-parts valuation based on net present value

  Citi uses an NPV-based SOTP method with WACC of 9.2%, beta of 1.0, and a perpetual growth rate of 3%, while extending revenue and earnings forecasts for different business segments to 2035E to derive target prices of Rmb160 for A-shares and HK$183 for H-shares.

• Fundamental researchManagement interviews and operating momentum verification

  Confirm revenue guidance, pipeline conversion, capacity, and regulatory risks through on-site research

  Based on the June 15, 2026 visit to the Shanghai headquarters and communication with management, the report focuses on verifying continuing-operations revenue, TIDES, small-molecule CDMO, gross margin, AI efficiency gains, and overseas capacity progress.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 603259.SS

  Core covered asset, WuXi AppTec A-shares

  Strengths

  A-share target price of Rmb160; business growth supported by TIDES, small-molecule D&M, AI efficiency gains, and pipeline conversion; Citi lists the company as one of its top picks.

  Weaknesses

  The extracted text did not disclose the current A-share price, so the A-share upside cannot be calculated from the original text; overseas capacity ramp-up may weigh on overall gross margin.

  Comparison

  Citi believes the A-shares are currently trading at about 17x 2026E PE, with an attractive valuation.

  Risks

  Declining customer outsourcing demand, talent retention, regulatory compliance, failure in overseas market expansion, failure to meet customer audit standards, rising labor costs, and U.S. sanctions.

• 2359.HK

  H-share of the same issuer; the report discloses both the H-share target price and current price

  Strengths

  H-share target price of HK$183, implying about 46.2% upside versus the disclosed current price of HK$125.2; core fundamentals are the same as the A-shares.

  Weaknesses

  The H-shares are also exposed to geopolitical, regulatory, and overseas execution risks.

  Comparison

  Citi believes the H-shares are currently trading at about 18x 2026E PE, and the valuation remains attractive.

  Risks

  U.S. sanctions, regulatory compliance, declining customer demand, slower-than-expected overseas capacity expansion, and rising costs.

• WuXi Chemistry

  Core business segment for valuation and earnings growth

  Strengths

  Contributes Rmb129.6/share in A-share SOTP and HK$148.3/share in H-share SOTP; the chemistry business gross margin is close to 50%.

  Weaknesses

  Overseas capacity expansion and ramp-up may create temporary margin pressure.

  Comparison

  It accounts for the largest value contribution in the SOTP breakdown and is the main source of the target price.

  Risks

  Project conversion, capacity utilization, customer audits, regulation, and international trade restrictions.

Key data

• 2026 continuing-operations revenue guidance18%-22% YoY growth; 22%-26% YoY growth on a constant-currency basisManagement maintained full-year revenue guidance and noted that revenue is recognized at the spot exchange rate at the time of monthly invoicing.
• Small-molecule CDMO growth80% YoY growth in 1Q26The report lists small-molecule manufacturing as one of the core growth drivers.
• TIDES revenue guidance40% YoY growth in 2026Management maintained the growth guidance for the TIDES business.
• Solid-phase peptide synthesis capacityIncrease from 100,000L in 3Q25 to 130,000L in 2026The additional capacity is mainly planned for clinical-stage pipelines.
• Gross margin trendThe company’s long-term gross margin guidance is 45%-50%; the chemistry business is currently close to 50%The ramp-up of overseas capacity may weigh on overall gross margin, but more Phase III and commercial projects should help expand margins.
• AI efficiency improvementAPI equipment utilization increased from 60% to 72%The self-developed Pyxis equipment scheduling system has covered more than 3,000 compounds and hundreds of reactor workflows.
• Revenue share of overseas capacityLess than 10% of total revenueThe company is advancing a multi-region capacity strategy across the United States, Europe, Singapore, and Saudi Arabia; U.S. DP capacity is expected to begin operations in 4Q26, and the first API workshop in Singapore is planned to start operations next year.
• Regulatory and geopolitical exposureRevenue exposure to federally funded projects is below 1%On June 11, 2026, the company sued the U.S. Department of Defense in the U.S. District Court for the District of Columbia regarding the 1260H list; management believes the Biosecure Act has a five-year grace period.
• A-share target priceRmb160The sum-of-the-parts valuation includes WuXi Chemistry at Rmb129.6/share, WuXi Testing at Rmb10.3/share, WuXi Biology at Rmb3.7/share, investment income at Rmb3.7/share, and other services plus net cash at Rmb12.6/share.
• H-share target priceHK$183The sum-of-the-parts valuation includes WuXi Chemistry at HK$148.3/share, WuXi Testing at HK$11.8/share, WuXi Biology at HK$4.3/share, investment income at HK$4.3/share, and other services plus net cash at HK$14.5/share.
• Current valuationA/H shares at about 17x/18x 2026E PE (BBG)Citi believes the current valuation is very attractive.

Impact & implications

The report carries a clearly positive implication for WuXi AppTec: if TIDES, small-molecule D&M, and AI efficiency gains continue to deliver, the company may sustain above-industry revenue and earnings growth; at the same time, the current valuation is attractive relative to the target price and the medium- to long-term growth narrative. It should be noted that overseas capacity ramp-up, customer demand, regulatory scrutiny, and U.S. sanctions may still affect valuation realization.

Risks

• Declining customer spending or demand for outsourced drug discovery, testing, development, and manufacturing.
• The company may be unable to attract, train, motivate, or retain highly skilled scientists and research technicians.
• Failure to comply with existing regulations or industry standards, or adverse actions by drug approval regulators.
• The company may be unable to successfully expand into or operate in new overseas markets.
• If it fails to meet customer audit and inspection standards, the company may be unable to continue serving customers.
• Rising labor costs may affect profitability.
• U.S. sanctions or other geopolitical restrictions may affect the business and valuation.

What to watch

• Whether continuing-operations revenue in 2026 can deliver 18%-22% YoY growth, and whether constant-currency growth can deliver 22%-26%.
• Whether the TIDES business can achieve 40% revenue growth in 2026, and whether solid-phase peptide synthesis capacity can increase to 130,000L as planned.
• Whether small-molecule CDMO can sustain strong orders and project conversion after its high growth in 1Q26.
• Whether the chemistry business gross margin can remain close to 50%, and the extent to which overseas capacity ramp-up drags on overall gross margin.
• Whether AI tools such as Pyxis can continue to improve API equipment utilization and expand to more workflows.
• Progress of U.S. DP capacity coming online in 4Q26, the Singapore API workshop beginning operations next year, and the early planning of the Saudi project.
• Changes in policies related to the 1260H list litigation, the Biosecure Act grace period, and U.S. sanctions.